Literature DB >> 9544214

Potent antagonists of somatostatin: synthesis and biology.

S J Hocart1, R Jain, W A Murphy, J E Taylor, B Morgan, D H Coy.   

Abstract

The search for synthetic analogues of somatostatin (SRIF) which exhibit selective affinities for the five known receptor subtypes (sst1-5) has generated a large number of potent agonist analogues. Many of these agonists display good subtype selectivities and affinities for the subtypes 2, 3, and 5, with very few selective for sst1 or sst4. Until the recent report by Bass and co-workers (Mol. Pharmacol. 1996, 50, 709-715; erratum, Mol. Pharmacol. 1997, 51, 170), no true antagonists had been discovered, let alone any displaying differential receptor subtype selectivity. In this present study, we explore the effect of this putative L5,D6 antagonist motif on various series of somatostatin agonist analogues, both linear and cyclic. It was found that many D5,L6 agonists could be converted into competitive antagonists by applying this motif, the most potent of which was H-Nal-cyclo[DCys-Pal-DTrp-Lys-Val-Cys]-Nal-NH2 (32). This antagonist was selective for hsst2 with an affinity of 75 nM and an IC50 of 15.1 nM against SRIF-14 in a rat in vitro antagonist bioassay. Receptor-selective somatostatin antagonists should provide valuable tools for characterizing the many important physiological functions of this neuropeptide.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9544214     DOI: 10.1021/jm970730q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

Review 1.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

2.  Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3.

Authors:  T Talme; J Ivanoff; M Hägglund; R J Van Neerven; A Ivanoff; K G Sundqvist
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

3.  Somatostatin-receptor 2 (sst2)-mediated effects of endogenous somatostatin on exocrine and endocrine secretion of the rat stomach.

Authors:  Vidar Fykse; David H Coy; Helge Lyder Waldum; Arne Kristian Sandvik
Journal:  Br J Pharmacol       Date:  2005-02       Impact factor: 8.739

4.  Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.

Authors:  C Petrucci; D Cervia; M Buzzi; C Biondi; P Bagnoli
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

5.  Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

Authors:  Judit Erchegyi; Renzo Cescato; Christy Rani R Grace; Beatrice Waser; Véronique Piccand; Daniel Hoyer; Roland Riek; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

6.  Synergistic Catalysis by "Polymeric Microzymes and Inorganic Nanozymes": The 1+1>2 Effect for Intramolecular Cyclization of Peptides.

Authors:  Zhiliang Chen; Börje Sellergren; Xiantao Shen
Journal:  Front Chem       Date:  2017-09-26       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.